← All Abbott Laboratories filings

Abbott Laboratories Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NYSE
ABT
Abbott Laboratories
SCHEDULE: Vanguard Discloses 7.5% Stake in Abbott Laboratories
Vanguard Capital Management has reported beneficial ownership of 130,676,776 shares, representing 7.5% of Abbott Laboratories' common stock as of March 31, 2026.
NYSE
ABT
Abbott Laboratories
SCHEDULE: Vanguard Group Reports 0% Stake in Abbott Labs
The Vanguard Group has amended its Schedule 13G filing for Abbott Laboratories, reporting 0% beneficial ownership following an internal realignment.
NYSE
ABT
Abbott Laboratories
SCHEDULE: Vanguard Amends Abbott Labs Ownership to 10.05%
The Vanguard Group has filed an amendment to its Schedule 13G, reporting a 10.05% beneficial ownership stake in Abbott Laboratories common stock.